<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Sweeps - Silver Star Spirits]]></title><description><![CDATA[Rivermark]]></description><link>https://www.rivermarkresource.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Tue, 28 Jul 2026 18:12:15 GMT</lastBuildDate><atom:link href="https://www.rivermarkresource.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[RIVERMARK MEDICAL ANNOUNCES FIRST PATIENT ENROLLED IN RAPID III CLINICAL STUDY EVALUATING THE FLOSTENT® SYSTEM]]></title><description><![CDATA[Rivermark Medical, a urology-focused medical device company committed toredefining benign prostatic hyperplasia (BPH) treatment through simple,innovative solutions, today announced the enrollment of the first patient inits RAPID III clinical study. RAPID III is a prospective, multicenter,randomized pivotal clinical trial (NCT06849258) designed to evaluate the safetyand effectiveness of the FloStent™ System in men experiencing lower urinarytract symptoms caused by BPH. The first procedure...]]></description><link>https://www.rivermarkresource.com/post/rivermark-medical-announces-first-patient-enrolled-in-rapid-iii-clinical-study-evaluating-the-floste</link><guid isPermaLink="false">6a58e84948b343e14f132ad5</guid><pubDate>Tue, 01 Apr 2025 05:00:00 GMT</pubDate><dc:creator>Greg Borecki</dc:creator></item><item><title><![CDATA[Rivermark Medical Closes $30 Million Series C Financing to Advance Development of FLOSTENT™ System for Benign Prostatic Hyperplasia]]></title><description><![CDATA[Milwaukee, WI – Rivermark Medical, a leader in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), today announced the close of a $30 million Series C financing round. The round was led by American Century Investments (ACI) including new investors Venture Investors Health Fund, Time BioVentures and an unnamed strategic investor, with follow-on participation from existing investors View Ventures, Cadence Healthcare Ventures, and Anduril Investors LLC. Funds will advance the...]]></description><link>https://www.rivermarkresource.com/post/rivermark-medical-closes-30-million-series-c-financing-to-advance-development-of-flostent-system-f</link><guid isPermaLink="false">6a58e8cf01e576df51c75904</guid><pubDate>Thu, 17 Oct 2024 05:00:00 GMT</pubDate><dc:creator>Greg Borecki</dc:creator></item><item><title><![CDATA[Rivermark Medical Announces Completion of Expanded Indication Study for the Flostent System]]></title><description><![CDATA[Clinical study evaluates the opportunity to treat patients suffering urinary retention due to benign prostatic hyperplasia Rivermark Medical, a company dedicated to developing a novel therapeutic device for benign prostatic hyperplasia (BPH), announced today the successful completion of its RAPID-UR study, an extended indication study that evaluated the use of the Company’s FloStent System in patients suffering urinary retention due to BPH. The pilot study included 11 patients, and procedures...]]></description><link>https://www.rivermarkresource.com/post/rivermark-medical-announces-completion-of-expanded-indication-study-for-the-flostent-system</link><guid isPermaLink="false">6a58e92501e576df51c759ce</guid><pubDate>Mon, 08 Jan 2024 06:00:00 GMT</pubDate><dc:creator>.</dc:creator></item><item><title><![CDATA[Rivermark Medical announces successful first-in-human use of its Flostent System For Symptomatic BPH]]></title><description><![CDATA[Company to expand clinical program as all treated patients experienced rapid symptom improvementMILWAUKEE, Jan. 10, 2023 /PRNewswire/--Rivermark MedicalTM, a company dedicated to developing first-line device therapy for benign prostatic hyperplasia (BPH), announced today the successful first-in-human (FIH) use of its FloStentTM System as part of the Company's RAPID-1 FIH clinical study. The procedures were performed on 15 patients by Principal Investigator (PI) Dr. Ingrid Perscky Arravanti...]]></description><link>https://www.rivermarkresource.com/post/rivermark-medical-announces-successful-first-in-human-use-of-its-flostent-system-for-symptomatic-bph</link><guid isPermaLink="false">6a58e96c48b343e14f132d31</guid><pubDate>Tue, 10 Jan 2023 06:00:00 GMT</pubDate><dc:creator>.</dc:creator></item></channel></rss>